Assessment of the efficacy of first-line antimalarial drugs after 5 years of deployment by the National Malaria Control Programme in Côte d'Ivoire

References

• World Health Organization (WHO). Guidelines for the Treatment of Malaria. 2nd ed. Geneva, Switzerland: WHO; 2010. Available from: http://whqlibdoc.who.int/publications/2010/9789241547925_eng.pdf. Accessed September 10, 2010.
   Google Scholar
• Enserink M. Malaria’s drug miracle in danger. Science. 2010;328(5980): 844–846.
   Web of Science ®Google Scholar
• White NJ. Artemisinin resistance – the clock is ticking. Lancet. 2010; 376:2051.
   PubMed Web of Science ®Google Scholar
• World Health Organization (WHO). Global Report on Antimalarial Efficacy and Drug Resistance: 2000–2010. Geneva, Switzerland: WHO; 2010. Available from: http://who.int/malaria/publications/atoz/9789241500470/en/index.html. Accessed May 14, 2011.
   Google Scholar
• Dondorp AM, Yeung S, White L, et al. Artemisinin resistance: current status and scenarios for containment. Nat Rev Microbiol. 2010;8(4): 272–280.
   PubMed Web of Science ®Google Scholar
• Dondorp AM, Nosten F, Yi P, et al. Artemisinin resistance in Plasmodium falciparum malaria. N Engl J Med. 2009;361(5):455–467.
   PubMed Web of Science ®Google Scholar
• World Health Organization (WHO). Global Plan for Artemisinin Resistance Containment (GPARC). Geneva, Switzerland: WHO; 2011. Available from: http://www.who.int/malaria/publications/atoz/artemisinin_resistance_containment_2011.pdf. Accessed May 29, 2011.
   Google Scholar
• Newton PN, Fernandez FM, Green MD, Primo-Carpenter J, White NJ. Counterfeit and substandard anti-infectives in developing countries. Antimicrobial Resistance in Developing Countries. 2010;(Pt 4): 413–443.
   Google Scholar
• Goodman C, Brieger B, Unwin A, et al. Medicine sellers and malaria treatment in sub-Saharan Africa: what do they do and how can their practice be improved? Am J Trop Med Hy. 2007;77(6):203–218.
   PubMed Web of Science ®Google Scholar
• Granado S, Obrist B, Manderson L, Tanner M. The moment of sale: treating malaria in Abidjan, Cote d’Ivoire. Anthropol Med. 2009; 16(3): 319–331.
   PubMedGoogle Scholar
• Aka E, Legris C, Tanimoto T, Matsushita R, Kimura K. Counterfeit medicine detection by authenticity investigation: a pilot study in the street market of Cote d’Ivoire. Jpn Soc Soc Pharm. 2005;24:7–16.
   Google Scholar
• Kamya MR, Yeka A, Bukirwa H, et al. Artemether-lumefantrine versus dihydroartemisinin-piperaquine for treatment of malaria: a randomized trial. PLoS Clin Trials. 2007;2:e20.
   PubMedGoogle Scholar
• Yeka A, Dorsey G, Kamya MR, et al. Artemether-lumefantrine versus dihydroartemisinin-piperaquine for treating uncomplicated malaria: a randomized trial to guide policy in Uganda. PLoS One. 2008;3:e2390.
   PubMed Web of Science ®Google Scholar
• Dorsey G, Staedke S, Clark TD, et al. Combination therapy for uncomplicated falciparum malaria in Ugandan children: a randomized trial. JAMA. 2007;297:2210–2219.
   PubMed Web of Science ®Google Scholar
• Mutabingwa TK, Anthony D, Heller A, et al. Amodiaquine alone, amodiaquine + sulfadoxine-pyrimethamine, amodiaquine + artesunate, and artemether-lumefantrine for outpatient treatment of malaria in Tanzanian children: a four-arm randomised effectiveness trial. Lancet. 2005;365:1474–1480.
   PubMed Web of Science ®Google Scholar
• Harrington WE, Mutabingwa TK, Muehlenbachs A, et al. Competitive facilitation of drug-resistant Plasmodium falciparum malaria parasites in pregnant women who receive preventive treatment. Proc Natl Acad Sci USA. 2009;106:9027–9032.
   PubMed Web of Science ®Google Scholar
• Mockenhaupt FP, Bedu-Addo G, Eggelte TA, et al. Rapid increase in the prevalence of sulfadoxine-pyrimethamine resistance among Plasmodium falciparum isolated from pregnant women in Ghana. J Infect Dis. 2008;198:1545–1549.
   PubMed Web of Science ®Google Scholar
• Vallely A, Vallely L, Changalucha J, Greenwood B, Chandramohan D. Intermittent preventive treatment for malaria in pregnancy in Africa: what’s new, what’s needed? Malaria J. 2007;6:16.
   PubMed Web of Science ®Google Scholar
• Tagbor H, Bruce J, Agbo M, Greenwood B, Chandramohan D. Intermittent screening and treatment versus intermittent preventive treatment of malaria in pregnancy: a randomised controlled non-inferiority trial. PLoS One. 2010;5(12):e14425.
   PubMed Web of Science ®Google Scholar
• Faye B, Offianan AT, Ndiaye JL, et al. Efficacy and tolerability of arte-sunate-amodiaquine (Camoquin plus) versus artemether-lumefantrine (Coartem) against uncomplicated Plasmodium falciparum malaria: multisite trial in Senegal and Ivory Coast. Trop Med Int Health. 2010;15(5):608–613.
   Web of Science ®Google Scholar
• Offianan AT, Penali LK, Yapi JD, et al. A comparative, randomized clinical trial of artemisinin/naphtoquine twice daily one day versus artemether/lumefantrine six doses regimen in children and adults with uncomplicated falciparum malaria in Cote d’Ivoire. Malaria J. 2009;8:148.
   Web of Science ®Google Scholar
• Ministry of Health/National Malaria Control Programme: Malaria policies and strategies in Côte d’Ivoire. Revised document, February 2008.
   Google Scholar
• Tipke M, Diallo S, Coulibaly B, et al. Substandard anti-malarial drugs in Burkina Faso. Malaria J. 2008;7:95.
   PubMed Web of Science ®Google Scholar
• Yavo W, Bla KB, Djaman AJ, et al. In vitro susceptibility of Plasmodium falciparum to monodesethylamodiaquine, quinine, mefloquine and halofantrine in Abidjan (Côte d’Ivoire). Afr Health Sci. 2010;10(2): 111–116.
   Web of Science ®Google Scholar
• World Health Organization (WHO). Assessment and Monitoring of Antimalarial Drug Efficacyfor the Treatment of Uncomplicated Falciparum Malaria. Volume 50. Geneva, Switzerland: WHO; 2003:1–68.
   Google Scholar
• World Health Organization (WHO). Malaria Terminology. Report of a drafting committee appointed by the World Health Organization. Geneva, Switzerland: WHO Monograph Series; 1953:82.
   Google Scholar
• World Health Organization (WHO). Methods and Techniques for Clinicals Trials on Antimalarial Drug Efficacy: genotyping to identify parasites population. Informal consultation organized by the Medicines for Malaria Venture and cosponsored by WHO; May 29–31, 2007; Amsterdam, The Netherlands.
   Google Scholar
• Cattamanchi A, Kyabayinze D, Hubbard A, Rosenthal PJ, Dorsey G. Distinguishing recrudescence from reinfection in a longitudinal anti-malarial drug-efficacy study: comparison of results based on geno-typing of msp-1, msp-2, and glurp. Am J Trop Med Hy. 2003;68: 133–139.
   PubMed Web of Science ®Google Scholar
• White NJ. Qinghaosu (artemisinin): the price of success. Science. 2008;320:330–334.
   PubMed Web of Science ®Google Scholar
• Bethell D, Se Y, Lon C, et al. Artesunate dose escalation for the treatment of uncomplicated malaria in a region of reported artemisinin resistance: a randomized clinical trial. PLoS One. 2011;6(5):e19283.
   PubMed Web of Science ®Google Scholar
• Noedl H, Se Y, Sriwichai S, et al. Artemisinin resistance in Cambodia: a clinical trial designed to address an emerging problem in Southeast Asia. Clin Infect Dis. 2010;51:e82–e89.
   PubMed Web of Science ®Google Scholar
• Tekete M, Djimde AA, Beavogui AH, et al. Efficacy of chloroquine, amodiaquine and sulphadoxine-pyrimethamine for the treatment of uncomplicated falciparum malaria: revisiting molecular markers in an area of emerging AQ and SP resistance in Mali. Malaria J. 2009;8:34.
   PubMed Web of Science ®Google Scholar
• Tinto H, Guekoun L, Zongo I, Guiguemde RT, D’Alessandro U, Ouedraogo JB. Chloroquine-resistance molecular markers (Pfcrt T76 and Pfmdr-1 Y86) and amodiaquine resistance in Burkina Faso. Trop Med Int Health. 2008;13:238–240.
   PubMed Web of Science ®Google Scholar
• Gbotosho GO, Sowunmi A, Happi CT, Okuboyejo TM. Therapeutic efficacies of artemisinin-based combination therapies in Nigerian children with uncomplicated falciparum malaria during five years of adoption as first-line treatments. Am J Trop Med Hyg. 2011;84(6): 936–943.
   Web of Science ®Google Scholar
• Ndiaye JL, Randrianarivelojosia M, Sagara I, et al. Randomized, multicentre assessment of the efficacy and safety of ASAQ – a fixed-dose artesunate-amodiaquine combination therapy in the treatment of uncomplicated Plasmodium falciparum malaria. Malaria J. 2009;8:125.
   PubMed Web of Science ®Google Scholar
• Adjei GO, Kurtzhals JA, Rodrigues OP, et al. Amodiaquine-artesunate vs artemether-lumefantrine for uncomplicated malaria in Ghanaian children: a randomized efficacy and safety trial with one year follow-up. Malaria J. 2008;7:127.
   PubMed Web of Science ®Google Scholar
• Owusu-Agyei S, Asante KP, Owusu R, et al. An open label, randomised trial of artesunate + amodiaquine, artesunate + chlorproguanil-dapsone and artemether-lumefantrine for the treatment of uncomplicated malaria. PLoS One. 2008;3:e2530.
   PubMed Web of Science ®Google Scholar
• Kobbe R, Klein P, Adjei S, et al. A randomized trial on effectiveness of artemether-lumefantrine versus artesunate plus amodiaquine for unsupervised treatment of uncomplicated Plasmodium falciparum malaria in Ghanaian children. Malaria J. 2008;7:261.
   PubMed Web of Science ®Google Scholar
• Koram KA, Abuaku B, Duah N, Quashie N. Comparative efficacy of antimalarial drugs including ACTs in the treatment of uncomplicated malaria among children under 5 years in Ghana. Acta Trop. 2005;95:194–203.
   PubMed Web of Science ®Google Scholar
• Kabanywanyi AM, Mwita A, Sumari D, Mandike R, Mugittu K, Abdulla S. Efficacy and safety of artemisinin-based antimalarial in the treatment of uncomplicated malaria in children in southern Tanzania. Malaria J. 2007;6:146.
   Web of Science ®Google Scholar
• Carrara VI, Zwang J, Ashley AA, et al. Changes in the treatment responses to artesunate-mefloquine on the northwestern border of Thailand during 13 years of continuous deployment. PLoS One. 2009;4:e4551.
   PubMed Web of Science ®Google Scholar
• Laufer MK, Djimde AA, Plowe CV. Monitoring and deterring drug-resistant malaria in the era of combination therapy. Am J Trop Med Hyg. 2007;77:160–169.
   Web of Science ®Google Scholar
• Stepniewska K, Taylor WR, Mayxay M, et al. In vivo assessment of drug efficacy against Plasmodium falciparum malaria: duration of follow-up. Antimicrob Agents Chemother. 2004;48:4271–280.
   PubMed Web of Science ®Google Scholar
• Bloland PB. Drug Resistance in Malaria. Geneva, Switzerland: World Health Organization; 2001.
   Google Scholar
• Krishna S, White NJ. Pharmacokinetics of quinine, chloroquine and amodiaquine. Clinical implications. Clin Pharmacokinet. 1996;30:263–299.
   PubMed Web of Science ®Google Scholar
• Badoe EV Lamptey R, Goka BQ. Amodiaquine-artesunate vs artemether-lumefantrine for uncomplicated malaria in Ghanaian children: a randomized efficacy and safety trial with one year follow-up. Malaria J. 2008;7:127.
   Web of Science ®Google Scholar